Novel small molecule anabolic agents for osteoporosis

Background:

Menopause significantly speeds bone loss and increases the risk of osteoporosis, a condition characterized by decreased bone mineral density and which impacts more than 200M people worldwide and contributing to over 2M fractures annually in the US alone. While several therapies exist, the current treatment landscape is defined by significant limitations: antiresorptive agents slow bone loss but do not rebuild it, and available anabolic options — largely injectable biologics — carry black box warnings, strict duration limits, and compliance challenges that undermine long-term patient outcomes. The opportunity for a safe, orally bioavailable small molecule that both protects and rebuilds bone represents one of the most compelling unmet needs in musculoskeletal medicine today.

Technology Overview:

Researchers at the University at Buffalo have developed a novel series of synthetic analogs derived from ferutinin, a naturally occurring phytoestrogen with demonstrated anti-osteoporotic activity comparable to estradiol benzoate. Ferutinin's biological profile is well-characterized — it limits bone resorption by inhibiting osteoclast differentiation while simultaneously promoting osteoblast activity, giving it a dual mechanism that natural and most synthetic competitors lack. However, natural ferutinin extracts are limited by variable efficacy and off-target effects, creating an opening for precision-engineered analogs. This invention advances two lead compositions within a rationally designed series, specifically engineered to:

• Retain and optimize the favorable estrogen receptor binding and bone-protective activity of the parent compound
• Minimize off-target effects through improved specificity relative to unrefined natural phytoestrogen extracts
• Incorporate antioxidant properties alongside antiresorptive and anabolic activity, offering a multifunctional therapeutic profile
• Support potential oral administration, eliminating the injection barrier that limits compliance with current anabolic therapies

Unlike existing treatments that provide only temporary efficacy windows or carry significant safety burdens, these analogs are designed with a profile that could support longer treatment durations and a more favorable risk-benefit balance.

Advantages:

• Regenerative/anabolic, not just antiresorptive
• Fewer potential side effects compared to standard antiresorptive treatments
• Improved safety and specificity compared to natural phytoestrogen extracts
• Potential for oral administration

Applications:

• Osteoporosis
• Hormone replacement therapy

Intellectual Property Summary: Patent pending

Stage of Development: In vitro

Licensing Status: Available for licensing or collaboration

About the Research Foundation for the State University of New York:

As the nation's largest research foundation supporting the nation's largest public university system, The Research Foundation for SUNY powers research and innovation to address today's most pressing problems and shape a better future for generations to come. The Research Foundations supports SUNY researchers leading the way globally in AI for the public good, quantum technologies, next-generation semiconductors, biotech and medicine, energy and climate solutions, and more. The Research Foundation for SUNY is a private, nonprofit educational corporation that is tax-exempt under Internal Revenue Code (IRC) Section 501(c)(3). To learn more, please visit us online at rfsuny.org.

About the State University of New York

The State University of New York is the largest comprehensive system of higher education in the United States, and more than 95 percent of all New Yorkers live within 30 miles of any one of SUNY’s 64 colleges and universities. Across the system, SUNY has four academic health centers, five hospitals, four medical schools, two dental schools, a law school, the country’s oldest school of maritime, the state's only college of optometry, 12 Educational Opportunity Centers, over 30 ATTAIN digital literacy labs, and manages one US Department of Energy National Laboratory. In total, SUNY serves about 1.7 million students across its portfolio of credit- and non-credit-bearing courses and programs, continuing education, and community outreach programs. SUNY oversees nearly a quarter of academic research in New York. Research expenditures system-wide are nearly $1.5 billion in fiscal year 2025, including significant contributions from students and faculty. There are more than three million SUNY alumni worldwide, and annually one in three New Yorkers who earn a college degree is a SUNY alum. To learn more about how SUNY creates opportunities, visit suny.edu.